A new report by the Institute for Clinical and Economic Review (ICER) finds that 2 amytrophic lateral sclerosis (ALS) drug candidates from Amylyx and Mitsubishi Tanabe Pharma America have “low long-term value at their current suggested prices. Although the drugs both provide some benefits over the standard of care, the benefits do not justify the high price tag, the report notes.
According to ICER CMO David Rind, the drug candidate from Amylyx is, “worth about $30,000. That is a lot of money over three years, potentially, to gain a few months of life at an annual cost. You might want to pay more than that, given what a horrible disease ALS is. But $169,000 per year is a ton of money for a drug like this.”
To read more, click here.
(Source: Endpoints News, August 19th, 2022)